
REFERENCES

- Adams J., Polson D.W. and Franks S. (1985):* Prevalence of polycystic ovaries in ovulatory women and those with idiopathic hirsutism. *Journal of Endocrinology*. 104: (Supplement). 37.
- Adashi E.Y. (1986):* Clomiphene citrate-initiated ovulation. A clinical update. *Seminars Reprod. Endocrinol.* 4: 255.
- Adashi E.Y., Rocke J.A., Sopp K.C., Mortin E.J., Wentz A.C. and Jones G.S. (1979):* Gestational outcome of clomiphene citrate related conception. *Fertil. Steril.* 31: 620-6.
- Aono T., Miyazaki M. and Migake A. (1977):* Responses of serum gonadotropins to LH-releasing hormone and estrogens in Japanese women with polycystic ovaries. *Acta. Endocrinologica*. 85-840.
- Bach L.A. and Rechler M.M. (1992):* Insulin-like growth factors and diabetes. *Diabetes and Metabolism. Review*; 8: 229-257.
- Baird D.T., Corker C.S., Davidson D.W., Hunter W.M. and Michie E.A. (1997):* Pituitary ovarian relationships in polycystic ovary syndrome. *Journal of clinical endocrinology and Metabolism*. 45: 798.
- Ballard J., Baxter R., Binoux M., Clemmons D., Drops S., Hall K., Hintz R., Rechler M., Rutanen E. and Schwander J. (1989):* On the nomenclature of the IGF binding proteins. *Acta Endocrinol*; 121: 751-752.
- Barbieri R.L. (1994):* Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress. *J. Reprod Med.* 39: 327.
- Barbieri R.L., Smith S. and Ryan K.J. (1988):* The role of hyperinsulinaemia in the pathogenesis of ovarian hyperandrogenism. *Fertil. Steril.* 50: 197.
- Barreca A., Minuto F. and Volpe A. (1990):* Insulin like growth factors and IGF-1 binding protein in the follicular fluids of growth hormone treated patients. *Clin. Endocrinol.* 32: 497.

Baserga R., Resnicoff M. and Dews M. (1997): The IGF-I receptor and cancer. *Endocrine*; 7: 99-103.

Baxter R. and Martin J. (1986): Radioimmunoassay of growth hormone-dependent insulin like growth factor binding protein in human plasma. *J. Clin. Invest.* 78: 1504-1512.

Baxter R.C. and Cowell C.T. (1987): Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. *J. Clin. Endocrinol. Metab.*; 65: 432-440.

Baxter R.C., Martin J.L. and Benioc V.A. (1989): High molecular weight insulin-like growth factor binding protein complex. *J. Biol. Chem.* 264: 11843-11848.

Bayes-Genis A., Conover C.A. and Schwartz R.S. (2000): The insulin-like growth factor axis: A review of atherosclerosis and restinosis. *Circ. Res.*; 86(2): 125-130.

Bell G.I., Merryweather J.P., Sanchez-Pescodor R., Stempien M.M., Priestley L., Sectt J. and Rall L.B. (1984): Sequence of a cDNA clone encoding human preproinsulin-like growth factor II. *Nature*; 310: 775-775.

Blum W.F. and Ranke M.B. (1990): Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. *Horm. Res.*; 34 (suppl): 31-37.

Blum W.F., Alberttson K., Roseberg S. and Rnake M.B. (1993): Serum levels of IGF-1 and IGFBP-3 reflect spontaneous GH secretion. *J. Clin. Endocrinol. Metab.*; 76: 1610-1630.

Blum W.F., Ranke M.B. and Bierich J.R. (1988): A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I. *Acta Endocrinol*; 118: 374-380.

Blum W.F., Ranke M.B., Kietzman K., Gouggel E., Zeisel H.J. and Bierich J. (1990): A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin binding protein: its use for diagnosis of GH deficiency. *J. Clin. Endocrinol. Metab.* 70: 1292-12298.

- Blum W.F., Ranke M.B., Lenchner B. and Bierich J.R. (1987):* The pleomorphic pattern of somatomedins during human development. *Acta Endocrinol*; 116: 445-451.
- Blum W.F., Ranke M.B., Kietzmann K., Tonshoff B. and Mehls O. (1989):* Excess of IGF-binding proteins in chronic renal failure: evidence for relative GH resistance and inhibition of somatomedin activity. In: Drop SLS, Hintz RL (eds) *Insulin-like growth factor binding proteins*. Excerpta Medica, Amsterdam; pp 93-101.
- Borgstrom L., Kagedal B. and Paulsen O. (1986):* Pharmacokinetics of N-acetyl cysteine in man. *Eur. J.clin. Pharmacol.* 31: 217-22.
- Bosenberg M.W. and Massague J. (1993):* Juxtacrine cell signaling molecules. *Curr. Opin. Cell. Biol.* 5: 832.
- Breothaupt T.B., Vazquez A., Baez I. and Eylar E.H. (1996):* the suppression of T cell function and NF (Kappa) B expression by serine protease inhibitors is blocked by N-acetyl cysteine. *cell immunol.* 173: 1323-1329.
- Burghen G.A., Givens J.R. and Kitabchi A.E. (1980):* Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. *J. Clin. Endocrinol. Metab.* 50: 113.
- Buttram V. and Reiter R.C. (1985):* Polycystic ovary syndrome. In : *Surgical treatment of the infertile female*. Williams and Wilkins. Baltimore. London. 229-284.
- Campbell P.G., Novak J.F., Yanosick T.B., McMaster J.H. (1992):* Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. *Endocrinology.* 130: 1401-1412.
- Cataldo N.A. and Gividee L.C. (1992):* Follicular fluid insulin-like growth factor binding proteins in polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 74: 695.
- Chang R.J., Mandel F.P., Lu J. K. and Judd H.L. (1982):* Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease. *J. Clin. Endocrinol. Metab.* 54: 490.

- Chang R.J., Nakamura R.M., Judd H.L. and Kaplan S.A. (1983):** Insulin resistance in non-obese patients with polycystic ovarian disease. *J. Clin. Endocrinol. Metab.* 57: 356.
- Chiao J.W., Chung F., Krzeminski J. et al., (2000):** Modulation of growth of human prostate cancer cells by N-acetylcysteine conjugate of phenethyl isothiocyanate. *Int. J. Oncol*;16:1215-1219.
- Christafori G., Nalk P. and Hanahan D. (1994):** A second signal supplies by insulin-like growth factor II in oncogene induced tumorigenesis. *Nature*; 369-414-417.
- Christman G.M., Randolph J.F. and Marshall J.C. (1991):** Reduction of gonadotropin releasing hormone pulse frequency is associated with subsequent selective follicle stimulating hormone secretion in women with PCOD. *J. Clin. Endocrinol. Metab.* 72: 1278.
- Ciampelli M. and Lanzone A. (1998):** Insulin and polycystic ovary syndrome: a new look at an old subject. *Gynecol Endocrinol* 12:277-292.
- Ciarldi T.P., Morales A.J. and Hickman M.G. (1999):** Insulin resistance in fibroblasts from subjects with polycystic ovary syndrome. *Metabolism.* 47: 940-946.
- Clark A.M., Thornely b., Tomlinson L., Gallety C. and Norman R.J. (1998):** Weight loss in obese infertile women results improvement in reproductive outcome for all forms of fertility treatment. *Hum. Reprod.* 13(6): 1502-5.
- Clemmons D.R. (1991):** Insulin-like growth factor binding proteins: Roles in regulating IGF physiology. *J. Dev. Physiol.*; 15: 105-110.
- Clemmons D.R., Busby W.H., Arai T., Nam T.J., Clarkse J.b., Jones J.I. and Ankrapp D.K. (1995):** Role of insulin-like growth factor (IGF) binding proteins in control of IGF actions. *Prog. Growth Factor Res.*; 6: 357-366.
- Clemmons D.R., Underwood L.E., Ridgway E.C., Kliman B. and Van-Wyk J.J. (1981):** Hyperprolactinemia is associated with increased immunoreactive somatomedin C in hypopituitarism. *J. Clin. Endocrinol. Metab.*; 52: 731-735.

- Clemmons D.R., Van-Wyk J.J., Ridgway E.C., Kliman B., Kjellberg R.N. and Underwood L.E. (1979):** Evaluation of acromegaly by radioimmunoassay of somatomedin-C.N. Engl. J. Med.; 301: 1138-1142.
- Clifford J. Rosen (1999):** Serum insulin-like growth factors and insulin-like growth factor-binding proteins: Clinical implications. Clinical chemistry; 45: 1384-1390.
- Coconi C., Cuello S., Cargnoni A. et al. (1988):** The role of glutathione status in the protection against ischemic and reperfusion damage effect of N-acetylcysteine. J.Mol. Cell. Cardiol. 20: 5-13.
- Cohen P., Groves H.C.b., Peehl D.M., Kamarek M., Guidice L.C. and Rosenfeld R.G. (1992):** Prostate specific antigen (PSA) is on IGF binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab.; 75: 1046-1053.
- Collins J.A. (1990):** Superovulation in the treatment of unexplained infertility. Seminars Reprod. Endocrinol. 8: 165.
- Conover C.A., Misra P., Hintz R.L. and Rosenfeld R.G. (1986):** Effect of an anti-insulin-like growth factor I receptor antibody on insulin-like growth factor II stimulation of DNA synthesis in human fibroblasts. Biochem. Biophys. Res. Commun; 139: 501-508.
- Costigan D.C., Guyda H.J. and Posner B.I. (1988):** Free insulin-like growth factor I (IGF-1) and IGF-II in human saliva. J. Clin. Endocrinol. Metab. 66: 1014-1018.
- Cross R.J., Elliott L.H., Morford L.A., Roszman T.L. and McGillis J.P. (1995):** Functional characterization of the insulin-like growth factor I receptor on Jurkat T-cells. Cell. Immunol. 160: 205.
- Czech M.P. (1989):** Signal transmission by the insulin-like growth factors. Cell; 59: 235.
- Dai J. and Baxter R. (1994):** Regulation in vivo of acid labile subunit of the rat serum insulin-like growth factor-binding protein complex. Endocrinology; 35: 2433-2441.

- cysteine, tourine, and oxerutin on skin and kidug damage on long-term experimented diabetes Diabet. 1 52: 499-505.
- Oh Y. (1997):* IGFBPs and neoplastic models: new concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine. 7: 115-117.
- Ohmura E., Okada M., Onoda N., Kamiya Y., Murakami H., Tsushima T. and Schizume K. (1990):* Insulin-like growth factor I and transforming growth factor-a as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res. 50: 103.
- Olefsky J.M. (1980):* Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes. 30: 148.
- Olefsky J.M. and Koltermen O.O. (1981):* Mechanism of insulin resistance in obesity and non insulin dependent diabetes mellitus. Am. J. Med. 70: 151.
- Ooi G.T. (1990):* Insulin-like growth factor-binding proteins (IGFBPs): more than just 1, 2, 3. Mol. Cell. Endocrinol.; 71: C39-C43.
- O'Rahilly S. and Moller D.E. (1992):* Mutant insulin receptors in syndromes of insulin resistance. Clin. Endocr. 36: pp. 121.
- Pache T.D., deLong F.H. and Hop W.C. (1993):* Association between ovarian change assisted by transvaginal sonography and clinical and endocrine signs of polycystic ovary syndrome. Fertil. 59: 544.
- Pasquali R., Vicennati V. and Gambineri A. (1998):* Influence of weight distribution of adipose tissue in functional hyperandrogenism contraception. May. 26(5): 372.
- Peterson S.W., Miller A.L., Kellehae R.S. and Murray E.F. (1983):* Insulin receptor down regulation in human erythrocytes. J. Biol. Chem. 258: 9605-7.
- Philippe F., Backeljauw, Louis E., Underwood and the GHIS Collaborative Group (2001):* therapy for 6.7-7.5 years with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome. Journal of Clinical Endocrinology and Metabolism. 86(4): 1504-1510.
- Phipps W.R. (2001):* Polycystic ovary syndrome and ovulation induction. Obstet. Gynecol. Clin. Mar. 25(1): 165-82.

- Daughaday E. and Rotwein P. (1989):** Insulin like growth factors I and II. Peptide, Messenger ribonucleic acid and gene structures, serum and tissue concentrations. *Endocrinol. Rev.* 10: 68-91.
- De Floa S., Bennicelic Camoirano A. et al. (1985):** In vivo effects of N-acetylglutathione on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. *Carcinogenesis*. 61: 1735-1745.
- De Leo V., La Marca A., Morgante G., Ciotta L., Mencaglia L., Cianci A. and Petraglia F. (2000):** Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome. *Human Reproduction*, Vol. 15, No. 11, 2302-2305, November.
- De Mattia G., Bravi M.C., Laurenti O., Cassone -Faldetta M., Proietti A., De Luca O., Armiento A. and Feni C. (1998):** Reduction of oxidative stress by oral N-acetyl L-cysteine treatment decrease plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. *Diabetologia* 41: 1342-6.
- De Vries N. and De flora S. (1993):** N-Acetyl-Cysteine. *J Cell Biochem.* 17f: 5270-5277.
- Derynck R. (1994):** TGF-beta receptor-mediated signaling. *Trends Biochem. Sci.* 19: 548.
- Devane G.W., Czekala M.M., Judd H.L. and Yen S.S.C. (1975):** Circulating gonadotropins, estrogen and androgens in polycystic ovarian disease. *Am. J. Obstet. Gynecol.* 121: 496.
- Down K. A. and Gibson M. (1999):** Clomiphene citrate therapy for luteal defect. *Fertil. Steril.*, 399:43.
- Druckmann R. and Rohr U.D. (2002):** IGF-1 in gynaecology and obstetrics. *Maturitas*. Apr 15;41 Suppl 1:S65-83.
- Dunaif A. (1995):** Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of

- non-insulin dependent diabetes mellitus. Am. J. Medication. 98: 33S.
- Dunaif A., Geen G. and Phelps R.G. (1991):** Acanthosis nigricans, insulin action and hyperandrogenism: Clinical histological, and biochemical finding. J. Clin. Endocrinol. Metab. 73: 590.
- Dunaif A., Graf M. and Mandeli (1987):** Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and or hyperinsulinemia. J. Clin. Endocrinol. Metab. 65:499.
- Easterling W.E., Talbert L.M. and Potter H.D. (1974):** Urinary testosterone levels in polycystic ovarian disease. Am. J. Obstet. Gynecol. 120: 385.
- Ellis M.J.C., Garmroudi F. and Cullen K.J. (1997):** Insulin receptors (IGF-I and IGF-II). In : Encyclopedia of cancer. 2nd ed., Vol. 2. M.R. Bertino (Ed.). New York. Academic Press, Pp. 927.
- Erickson G.F., Magoffin D.A. and Graguin R. (1990):** The effects of insulin and insulin like growth factors I and II on estradiol production of the granulosa cells of polycystic ovaries. J. Clin. Endocrinol. Metab. 70: 894.
- Erikson G.F., Hsueh A.J., Wuigley M.E., Rebar R.W. and Yen S.S.C. (1979):** Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries. J. Clin. Endocrinol. Metab. 49: 514.
- Fedi P., Tronick S.R. and Aaronson S.A. (1993):** Growth factors. In : Cancer Medicine. 4th ed., J.F., Holland; R.C. Bast. Jr. D.L. Morton. E. Frei III. D.W., Kufe and R.R. Weichselbaum (eds.) Baltimore. Williams and Wilkins. Pp. 41.
- Ferrannini E. (1998):** Insulin resistance versus insulin deficiency in non-insulin dependent diabetes mellitus, problems and prospects. Endocrinol. Rev. 19:477.
- Flier J.S., Kahn C.R. and Roth J. (1996):** Receptor, antireceptor antibodies and mechanism of insulin resistance. N. Engl. J. Med. 330:413.

- Fowlkes J., Engchild J., Suzuki K. and Nagase H. (1994):* Matrix metalloproteinases degrade IGFBP-3 in dermal fibroblast cultures. *J. Biol. Chem.*; 269: 25742-25746.
- Fritz M.A., Holmes R.T. and Keenan E.J. (1991):* Effect of clomiphene citrate treatment on endometrial estrogen and progesterone receptor induction in women. *Am. J. Obstet. Gynecol.* 165: 177.
- Frnaks S., Adams J., Mason, H.D. and Polson D.W. (1985):* Ovulatory disorders in women with polycystic ovary syndrome. In : *Clinics in Obstetrics and Gynecology.* 12 (3): 605-627,
- Frohman L.A., Downs T.R., Kelijman M., Clarke I.J. and Thomas G. (1990):* Somatomedin secretion and action in the regulation of growth hormone secretion. *Metabolism.*; 39: 43-45.
- Frystyk J. and Baxter R.C. (1998):* Competitive binding assay for determination of rat insulin-like growth factor binding protein-3. *Endocrinology*; 139: 1454-1457.
- Fulghesu A.M., Ciampelli M., Muzj G., Belosi C., Selvaggi L., Ayala G.F. and Lanzone A. (2002):* N-acetyl cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. *Fertil. Steril.* 77: 1128-35,
- Futterweit W. (1984):* Polycystic ovarian disease. Springer-Verlag, New York. 163.
- Galbay K.H., Deluca K., Fisher T.W., Mako M.E. and Rubenstein A.H. (1976):* Familial hyperinsulinemia: an autosomal dominant defect. *N. Engl. J. Med.* 294- 911.
- Gargosky S.E., Hasegawa T., Hasegawa Y., Tapainen P., MacGillivray M.H. and Rosenfeid R.G. (1992):* Clinical potential of urinary insulin-like growth factor binding-protein-3 (IGFBP-3) 2nd international workshop on insulin-like growth factor binding proteins, Opio (Coted'Azur), Franca (Abstract 93A).
- Gavish D. and Breslow J.L. (1991):* Lipoprotein (a) reduction by N-acetyl cysteine lancet. 337: 203-204.
- Gerli S., Gholomi N., Manna A., Diferga A.S., Vitiello C. and Unfer V. (2000):* Use of ethinyl to reverse the antiestrogenic effects of clomiphene citrate in patients undergoing intra-uterine

- insemination: a comparative randomized. Study Fertil. 73(1): 85-9.
- Ginsburg J. and Harvard C.W.H. (1976):* Polycystic ovary syndrome. Br. Med. Jr. 25: 737.
- Guidice L.C., Farrell E.M., Pham H., Lamson G. and Rosenfeld R.G. (1990):* Insulin-like growth factor binding proteins in maternal serum throughout gestation and the post-puerperium: effects of a pregnancy associated serum protease activity. J. Clin. Endocrinol. Metab. 71: 806-816.
- Given J.R. (1989):* Familial polycystic ovarian disease. Endocrinol. Metab. Clin. North Am. J. 17: 771.
- Gluckman P.D. and Ambler G.R. (1993):* What is the function of circulating insulin-like growth factor-II in postnatal life. Mol. Cell. Endocrinol.; 92: C1-C3.
- Goldstein S.R., Siddhanti S., Ciaccia A.V. and Plouffe L. (2000):* The pharmacological review of selective estrogen receptor modulator. Hum. Reprod. Update 6 (3): 212-24.
- Goldzieher J.W. (1981):* Polycystic ovarian disease. Fertil. Steril. 35-371.
- Goldzieher J.W. and Axelord L.R. (1963):* Clinical and biochemical features of polycystic ovarian disease. Fertil. Steril. 14: 631.
- Goldzieher J.W. and Di-Zerg G.S. (1985):* Polycystic ovarian disease. In: Clinical reproductive endocrinology. Shearmen, R.B. ed. Churchill Livingstones. Edinburg. 406.
- Guevara-Aguirre J., Rosenfeld R. et al. (1993):* Growth hormone receptor deficiency in Ecuador: Clinical and biochemical phenotype in two populations. J. Clin. Endocrinol. Metab.; 76: 417-423.
- Guler H.P., Zapf J., Schmid C. and Froeschh E.R. (1989):* Insulin-like growth factors I and II in healthy man. Estimation of half-lives and production rates. Acta Endocrinologica 121: 753-758.
- Hall K., Bong P. and Brismar K. (1995):* Insulin-like growth factors, future treatment in catabolism. Lakartidningen; 6(26-27): 2666-2671.

- insemination: a comparative randomized. Study Fertil. 73(1): 85-9.
- Ginsburg J. and Harvard C.W.H. (1976):** Polycystic ovary syndrome. Br. Med. Jr. 25: 737.
- Guidice L.C., Farrell E.M., Pham H., Lamson G. and Rosenfeld R.G. (1990):** Insulin-like growth factor binding proteins in maternal serum throughout gestation and the post-puerperium: effects of a pregnancy associated serum protease activity. J. Clin. Endocrinol. Metab. 71: 806-816.
- Given J.R. (1989):** Familial polycystic ovarian disease. Endocrinol. Metab. Clin. North Am. J. 17: 771.
- Gluckman P.D. and Ambler G.R. (1993):** What is the function of circulating insulin-like growth factor-II in postnatal life. Mol. Cell. Endocrinol.; 92: C1-C3.
- Goldstein S.R., Siddhanti S., Ciaccia A.V. and Plouffe L. (2000):** The pharmacological review of selective estrogen receptor modulator. Hum. Reprod. Update 6 (3): 212-24.
- Goldzieher J.W. (1981):** Polycystic ovarian disease. Fertil. Steril. 35-371.
- Goldzieher J.W. and Axelord L.R. (1963):** Clinical and biochemical features of polycystic ovarian disease. Fertil. Steril. 14: 631.
- Goldzieher J.W. and Di-Zerg G.S. (1985):** Polycystic ovarian disease. In: Clinical reproductive endocrinology. Shearmen, R.B. ed. Churchill Livingstones. Edinburg. 406.
- Guevara-Aguirre J., Rosenfeld R. et al. (1993):** Growth hormone receptor deficiency in Ecuador: Clinical and biochemical phenotype in two populations. J. Clin. Endocrinol. Metab.; 76: 417-423.
- Guler H.P., Zapf J., Schmid C. and Froeschh E.R. (1989):** Insulin-like growth factors I and II in healthy man. Estimation of half-lives and production rates. Acta Endocrinologica 121: 753-758.
- Hall K., Bong P. and Brismar K. (1995):** Insulin-like growth factors, future treatment in catabolism. Lakartidningen; 6(26-27): 2666-2671.

- Hammond C.B., Wlebe R.H., Haney A.F. and Yancy S.G. (1989):** Ovulation induction with luteinizing hormone releasing hormone in amenorrheic, infertile women. *American Journal of Obstetrics and Gynecology*. 135: 924.
- Heldin C.H., Welsh L.C., Miyazono K. and Westermarck B. (1997):** Growth regulatory proteins and their receptors in: *Encyclopedia of cancer*. 2nd ed., Vol. 2. J.R. Bertino (Ed.). New York. Academic Press. Pp. 772.
- Hellawell G. and Brewster S. (2002):** Growth factors and their receptors in prostate cancer. *BJU. Int.* Feb. 89(3): 230-40.
- Herington A.C. (1991):** Insulin-like growth factor: biochemistry and physiology. In *Baillier's clinical endocrinology* and D.M. Robertson and A.C. Herington (eds.) London. Bailliere Tindall. Pp. 531.
- Hintz R.L. (1981):** The somatomedins. *Adv. Pediatr.* 28: 293-317.
- Hizuka N., Takano K., Tanaka I., Asakawa K., Miyakawa M., Horikawa R., Shizume K. (1987):** Demonstration of insulin-like growth factor I in human urine. *J. Clin. Endocrinol. Metab.*; 64: 1309-1312.
- Hoeger K. (2001):** Obesity and weight loss in polycystic ovary syndrome. *Obstet. Gynecol. Clin. North Am. Marg.* 28(1): 85-97.
- Holman S.R. and Baxer R.C. (1996):** IGFBP-3: factors affecting binary and ternary complex formation. *Growth Regul.*; 6: 42-47.
- Holte J., Bergh Berne C., Berglund L. and Lithell H. (1994):** Enhanced early insulin response to glucose in relation to insulin resistance in women with poly-cystic ovary syndrome and normal glucose tolerance. *J. clin. Endocrinol. Metab.* 78: 1052-8.
- Hossenlopp P., Segovia B., Lassare C., Roghani M., Bredon M. and Binoux M. (1990):** Evidence of enzymatic degradation of insulin-like growth factor binding proteins in the 150K complex during pregnancy. *J. Clin. Endocrinol. Metab.*; 70: 797-805.
- Huppert L.C. (1979):** Induction of ovulation with clomiphene citrate. *Fertil. Steril.* 31: 1.

- Insler V. and Lunenfeld B. (1991):* pathophysiology of polycystic ovarian disease. *New insight Hum Reprod*, 6-1025.
- Isley W.L., Underwood L.E. and Clemmons D.R. (1983):* Dietary components that regulate serum somatomedin-C concentrations in human. *J. Clin. Invest.*; 175-182.
- Iverson O.H. and Elgjo K. (1997):* Growth regulation by endogenous growth suppressor peptides. In : *Encyclopedia of cancer*. 2nd ed., Vol. 2, J.R. Bertino (ed.). New York. Academic Press. Pp. 7600.
- Jialol I., Nailor P., Reddi K., Moodley J. and Jouhert S.M. (1987):* Evidence for insulin resistance in non-obese patient with polycystic ovary. *J. Clin. Endocrinol. Metab.* 64: 1060,
- Jones J.I. and Clemmons D.R. (1995):* Insulin-like growth factors and their binding proteins: biological actions. *Endocr. Rev.*; 16: 3-34.
- Jorgensen J.O.L., Blum W.F., Molle N., Ranke M.B., and Christiansen J.S. (1990):* Circadian patterns of serum insulin-like growth factor (IGF) II and IGF binding protein 3 in growth hormone deficient patients and age-and sex-matched normal subjects. *Acta Endocrinol. (Copenh)*; 123: 257-262.
- Judd H.J., Nephreson R.A., Pakoff J.S. and Yen S.S.C. (1977):* Correlation of the effects of dexamethasone administration on urinary 17-ketosteroid and serum androgen levels in patients with hirsutism. *AM. J. Obstet. Gynecol.* 128: 403,
- Kanzaki S., Hilliker S., Baylink D.J. and Mohan S. (1994):* Evidence that human bone cells in culture produce IGFBP-4 and IGFBP-5 proteases. *Endocrinology*; 134-383-392.
- Kawabi-Addo B., Ropiquet F., Giri D. and Ittnman M. (2001):* Alternative splicing of fibroblast growth factor receptors in human prostate cancer. *Prostate.* 46(2): 163-72,
- Kazer R.R., Kesel B. and Yen S.S.C. (1987):* Circulating LH pulse frequency in women with polycystic ovaries. *J. Clin. Endocrinol. Metab.* 65: 233.
- Kelly RG, Nally K, Shanahan F, O'Connell J. (2002):* type I insulin like growth factor receptor expression on colorectal carcinoma

- cell lines is decreased in response to the chemopreventive agent N-acetylcysteine. *Ann N Y Acad Sci.* Nov;973:555-8.
- Kessel B. and Hsueh A.J.W. (1987):** Clomiphene citrate follicle-stimulating hormone-induced luteinizing hormone receptor content in cultured rat granulosa cells. *Fertil. Steril.* 46: 532.
- Kettle L.M., Roseff S.J., Berga S.L., Mortola J.F. and Yen S.C.C. (1993):** Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovarian syndrome. *Fertil. Steril.* 59: 532.
- Kiddy D.S., Hamilton-Fairely D. and Bush A. (1992):** Improvement in endocrine and ovarian function dietary treatment of obese women with polycystic ovary syndrome. *Clin. Endocrinol. (Oxf).* 36: 105-11.
- Kiess W., Greensmin L.A., While R.M., Lee L., Rechler M.M., Nissley S.P. (1987):** type II insulin-like growth factor receptor is present in rat serum. *Proc. Nat. Acad. Sci.; USA* 84: 7720-7724.
- Kim H., Nagalla S.R., Oh Y., Wilson E., Roberts C.T. and Rosenfeld (1997):** Identification of a family of low affinity insulin-like growth factor binding proteins (IGFBPs): Characterization of connective tissue growth factor (CTGF) as a member of IGFBP superfamily. *Proc. Natl. Acad. Sci. USA;* 94: 12981-12986.
- Klagsbrun M. and Baird A. (1991):** A dual receptor system is required for basic fibroblast growth factor activity. *Cell.* 67: 229.
- Knapp R.G. and Miller M.C (1992):** Clinical epidemiology and biostatistics. National Medical Series from Williams & Wilkins. Baltimore, Hong Kong, London, Sydney, Egyptian edition. P: 209.
- Kokia, E. (1990):** addition of exogenous estrogens to improve cervical mucous following clomiphene citrate medication, *Acta Obstet Gynecol Scand* 69: 139.
- Lachelin G.C., Barnett M.S., Hopper B.r. (1979):** Adrenal function in normal women and women with the polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 49: 892.

- Lachelin G.C.L. (1984):* The polycystic ovary syndrome. In : Progress in Obstetrics and Gynecology. Studd. J. (ed). Churchill Livingstone. 4: 290-299.
- Lackey R.B., Gray S.L., Henricks D.M. (1999):* The insulin like growth factor (IGF) system and gonadotropin regulation, action and interaction-cytokine growth factor. Rev. 10-201.
- Lappas M., Permezel M. and Rice G.E. (2003):* N-acetyl cysteine inhibits phospholipids metabolism. Proinflammatory cytokine release, protease activity and nucleon factor-kappa B deoxyribonucleic acid binding activity in human fetal membranes in vitne. J. Clin. Endocrinol. Metab. 88: 1723-9.
- Laurence M. Demers (2001):* Pituitary function. In Tietz text book fundamental of clinical chemistry 5th ed. Eds by carl A Brutis and Edward R.Ashwood. W.B. Saunders USA; 822-838.
- Leblanc H., Lachelin G.C. and Abu-Fadil S. (1976):* Effect of dopamine infusion on pituitary hormone secretion in humans. J. Clin. Endocrinol. Metab. 43: 668.
- Lee P.D.K. and Rosenfeld R.G. (1987):* Clinical utility of insulin-like growth factor assays. Pediatrician; 14: 154-161.
- Lee P.D.K., Hintz R.L., Rosenfeld R.G. and Benitz W.E. (1988):* Present of insulin growth factor receptors and lock of insulin receptors on fetal bovine aortic smooth muscle cells. In Vitro Cell Dev. Biol.; 24: 921-926.
- Lee P.D.K., Wilson D.M., Rountree L., Hintz R.L., Rosenfeld R.G. (1990):* Efficacy of insulin-like growth factor I levels in predicting the response to provocative growth hormone testing. Pediatr. Res. 27: 45-51
- LeRoith D., Parrizas M. and Blakesley V.A. (1997):* IGF-I receptor and apoptosis. Endocrine; 7: 103-105.
- LeRoith D., Werner H., Beitner-Johnson D. and Roberts C.T. Jr. (1995):* Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev.; 16: 143-163.
- Lewitt M.S., Saunders H., Cooney G.J. and Baxter R.C. (1993):* Effect of human insulin-like growth factor binding protein-1 on the

- has no impact on malignant progression. *Nutr Cancer.*; 43(1):59-66.
- Matteri R.K., Starczyk F.Z., Gentzscheir E.E., Delgado C. and Lobo R.A. (1989):* Androgen sulfate and glucoronide conjugates in non hirsute and hirsute women with polycystic ovarian syndrome. *Am.J. Obstet. Gynecol.* 161: 1704.
- Melmed S. (1996):* Unwanted effects of growth hormone excess in adults. *J. pediatr. Endocrinol. Metab.* 9 (Suppl. 3); 369-374.
- Miles L.E.M., Lipschitz D.A., Bieber C.P. and Cook J.D. (1974):* Measurement of serum ferritin by a two site immunoradiometric assay. *Analyt. Biochem.*; 61: 209-224.
- Moggetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., Zanolin E. and Muggeo M. (2000):* Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized double blind, placebo-controlled 6-month trial, followed by open, longterm clinical evaluation. *J. Clin. Endocrinol. Metab.* 85: 139-46.
- Morgan D.O., Edmon J.C., Standring D.N., Fried V.A., Smith M.C., Roth R.A. and Rutter W.J. (1987):* Insulin-like growth factor II receptor as a multifunctional binding protein. *Nature*; 329: 301-307.
- Murdoch A.P., McClean K.G., Watson M.J., Dunlop W. and Kendall T.P. (1989):* Treatment of hirsutism in polycystic ovary syndrome with bromocriptine. *Br. J. Obstet. Gynecol.* 94: 385-65.
- Nestler J.E., Power L.P. and Matt D.W. (1991):* A direct effect of hyperinsulinaemia on serum sex hormone-binding globulin levels in obese women with the PCOS. *J. Clin. Endocrinol. Metab.* 72: 83.
- Nunley W.C., Vatemán B.Cr. Kitchen J.D. (1985):* Reproductive performance of patients treated with clomiphene citrate. *South Med. J.* 78: 31-33.
- Odestti P., Pesce C., Traverso N., Menini S., Maineri E.P., Cassol Valentini S., Patric S., Colta Isso D.M., Arinani U.M. and Pronzato M.A. (2003):* Comparative trial of N-actyl

- half life and action of administered insulin-like growth factor I in rats. *Journal of Endocrinology*; 136; 253-260.
- Li S.L., Goko H., Xu Z.D., Kimura G., Sun Y., Kawachi M.H., Wilson T.G., Wilczynski S. and Fujita-Yamaguchi Y. (1998):* Expression of insulin-like growth factor (IGF)-II in human, prostate, breast, bladder and paraganglino tumors. *Cell tissue. Res.*; 291(3): 469-479.
- Li T., Warren M.A., Murphy C., Sargeant S. and Cooke J.D. (1992):* A prospective randomized, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. *Br. J. Obstet. Gynecol.* 99: 1008.
- Lobo A. and Crange L.R. (1981):* Elevation in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with polycystic ovarian disease. *J. Clin. Endocrinol. Metab.* 52: 156.
- Lobo R.A. (1991):* Hirsutism in polycystic ovary syndrome : current concepts. *Clin. Obstet. Gynecol.* 34: 817-26.
- Lobo R.A., Kletzky O.A., Campeau J.D. and Dizerge G.S. (1983):* Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome. *Fertil. Steril.* 39: 674.
- Logan A. (1990):* Intracrine regulation at the nucleus-a further mechanism of growth factor activity? *Endocrinol.* 125: 339.
- Luciano A.A., Chapler F.K. and Sherman B.M. (1984):* Hyperprolactinemia in PCOS. *Fertil. Steril.* 41: 719.
- Mantazoros C.S., Tzonou A., Signerello L.B., Stampfer M., Trichopoulos D. and Adami H.O. (1997):* Insulin like growth factor I in relation to prostate cancer and benign prostatic hyperplasia. *Br. J. Cancer.* 76(9): 1115.
- Martin J.B. (1973):* Neural regulation of growth hormone secretion. *N. Engl. J. Med.*; 288: 1348-1393.
- Martin KR, Saulnier MJ, Kari FW, Barrett JC, French JE (2002):* Timing of supplementation with the antioxidant N-acetyl-L-cysteine reduces tumor multiplicity in novel, cancer-prone p53 haploinsufficient Tg.AC (v-Ha-ras) transgenic mice but

- Rechler M. (1993):* Insulin-like growth factor binding proteins. *Vit. Horm.* 47: 1-114.
- Regan L., Owen E.J. and Jacobs H.S. (1990):* Hypersecretion LH. Infertility and Miscarriage. *Lancet.* 336: 1141-4.
- Ristow M., Muller-Wieland D. and Pfeiffer A. (1998):* Obesity associated with mutation of genetic regulator or adipocyte differentiation. *N. Engl. J. Med.* 339:953.
- * *Rizk A.Y., Bedaiwy M.A. and Al-Inany H.G. (2005):* N-aceytlcysteine is a novel adjuvant to clomiphene citrate in clomiphene resistant polycystic ovary syndrome. *Fertil Steril.* 83(2):367-70.
- * *Rizk A.Y., Bedaiwy M.A. and Al-Inany H.G. (2005):* N-aceytlcysteine is a novel adjuvant to clomiphene citrate in clomiphene resistant polycystic ovary syndrome. *Fertil Steril.* 83(2):367-70.
- Rosen C.J., Donahu L.R. and Hunter S.J. (1994):* Insulin-like growth factors and bone: the osteoporosis connection. *Proc. Soc. Exp. Boil. Med.* 206(2): 83-102.
- Rosenbaum D., Haber R.S. and Dunaif A. (1993):* Insulin resistance in polycystic ovary syndrome, decreased expression of GLUT-4 glucose in adipocystes. *Am. J. Physiol.* 264-E. 197.
- Rosenfeld R.G., Wilson D.M., Lee P.D.K. and Hintz R.L. (1986):* Insulin-like growth factors I and II in evaluation of growth retardation. *J. Pediatr.* 109: 428-433.
- Rosenfield R.L. (1979):* Plasma free androgen pattern in hirsute women and their diagnostic implication. *Am. J. Med.* 66: 417.
- Rosenfield R.L., Barnes R.B., Care J.F. and Lucky A.W. (1990):* Dysregulation of cystochrome P450c 17-alpha as the cause or polycystic ovarian syndrome. *Fertil. Steril.* 53: 785.
- Rudman D., Feller A.G. and Nelgrag H.S. (1990):* Effect of human GH in men over age 60. *N. Engl. J. Med.* 323: 52-60.
- Russel P.J., Bennett S. and Stricker P. (1998):* Growth factory involvement in progression of prostate cancer. *Clin. Chem.* 44(4): 705.

- Rust L.A., Israel R. and Mishell D.R. (1974):* An individualized graduated therapeutic regime for clomiphene citrate. *Am. J. Obstet. Gynecol.* 120: 785.
- Rutanen E.M. (1998):* Insulin-like growth factors in endometrial function. *Gynecol. Endocrinol.* 12(6): 399.
- Salomon W.D. and Daughaday W.H. (1957):* A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. *J. Lab. Clin. Med.* 49: 825-836.
- Sara V.R. and Hall K. (1980):* Somatomedins in the fetus. *Clin. Obstet. Gynecol.* 23: 765.
- Sasaki N., Rees-Jones R.W., Zick Y., Nisseley S. P. and Rechler M.M. (1985):* Characterization of insulin-like growth factor I (IGF0-I)-stimulated tyrosin kinase activity associated with the B-subunit of type I IGF receptors of rat liver cells. *J. Biol. Chem.* 260: 9793.
- Scarlett J.A., Kolterman O.C. and Olfsky J.M. (1982):* Insulin resistance and diabetes due to a genetic defect in insulin receptors. *J. Clin. Endocrinol. Metab.* 55: 123.
- Schachter M. (1993):* Hypergonadotropic patients with ultrasonographically detected polycystic ovaries have aberrant gonadotropin secretion when treated with pulsatile gonadotropin releasing hormone. A new insight to the pathophysiology of polycystic ovary syndrome. *Fertil. Steril.* 59: 479-82.
- Schwander J.C., Hauri C., Zapf J. and Froesch E.R. (1983):* Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. *Endocrinology.* 113: 297-305.
- Sekhon B., Sekhon C., Khan M., Patel S.J., Singh I. and Singh A.K. (2003):* N-acetyl cysteine protects against injury in a rat model of focal cerebral ischemia brain REs. 971: 1-8.
- Shearman R.P. (1986):* Hirsutism and virilism. In : Dewhurst's textbook of obstetrics and Gynecology for postgraduates. Whitfield. C.R. (ed.). Blackwell Science publications. Pp. 80-90.

- Shepard P.R., Withers D.J. and Siddle K. (1998):* Phosphoinositide 3-kinase. The key switch mechanism in insulin signaling. *Biochem. J.* 333- 471.
- Shimasaki S., Uchiyama F., Shimonaka M. and Ling N. (1990):* Molecular cloning of the cDNAs encoding a novel insulin-like growth factor-binding protein from rat and human. *Mol. Endocrinol.*; 4: 1451-1458.
- Silfen M E., Denburg M R., Manibo A.M., Lobo R.A., Jaffe R., Ferin M., Levine L.S. and Oberfield S.E. (2003):* Early Endocrine, Metabolic, and Sonographic Characteristics of Polycystic Ovary Syndrome (PCOS): Comparison between Nonobese and Obese Adolescents. *The Journal of Clinical Endocrinology & Metabolism* Vol. 88, No. 10 4682-4688
- Sjodin K., Nilsson E., Hallberg A. and Tunek (1989):* Metabolism of N-acetyl cysteine. *Biochem. Pharm.* 38: 3981-3985.
- Smith G.C. and Franks S. (1993):* Polycystic ovary syndrome. *Reproductive Medicine Review.* 2: 15-32.
- Soliman A.T., Hassan A.E.H.I., Aref M.K., Hintz R.L., Rosenfeld R.G. and Rogol A.D. (1986):* Serum insulin-like growth factors I and II concentrations and growth hormone and insulin responses to arginine infusion in children with protein-caloric malnutrition before and after nutritional rehabilitation. *Pediatr. Res.* 20: 1122-1130.
- Spereepapaong W., Suwajanakorn S., Triratanachai S. et al. (2000):* Effect of clomiphene citrate on the endometrium of regularly cycling women. *Fertil.* 73(2): 287-91.
- Speroff L., Glass R.H. and Kase N.G. (1999):* anovulation and polycystic ovaries. In : Speroff L., Glass R., N.G. (eds). *Clinical Gynecologic Endocrinology and infertility* (Sixth Edition). Williams and Wilkins. Baltimore Maryland. 487: 513.
- Speroff L., Glass R.H. and Kase N.G. (1994):* Anovulation. In : *Clinical Gynecologic Endocrinology and Infertility*. Williams and Wilkins Co. 185-198.
- Sporn M.B. and Tadaro G.J. (1980):* Autocrine secretion and malignant transformation of cells. *N. Engl. J. Med.* 303: 878.

- Spruce B.A., Kendall-Taylor P., Dunlop W., Anderson A.J., Wastson M.J., Cook D.B. and Gray C. (1984):* The effect of bromocriptine in the polycystic ovary syndrome. *Clinical Endocrinology*. 20: 481.
- Stein Kretzer M.P., Kretzer P.A., McElory E. and Connway Mayers B.A. (1992):* A simplified approach to in-vitro fertilization. *J. Reprod. Med.* 37: 199-204.
- Stuart C.A., Peters E.J., Prince M.D., Richards G., Cavallo A. and Meyer W.J. (1986):* Insulin resistance with acanthosis nigricans. The roles of obesity and androgen excess. *Metabolism*. 35: 197.
- Sumantran V.N. and Wicha M. (1995):* Regulation of tumor cell growth. In : *Clinical oncology*. 1st ed., M.D., Abeloff. J.O. Armitage. A.S. Lichter and J.E. Aneiderhuder (Eds.). New York. Churchill Livingstone. Pp. 77.
- Takai I., Tau S., Takakura K. and Mari T. (1991):* Three types of polycystic ovarian disease in relation to androgenic function. *Fertil. Steril.* 65: 5, 856.
- Tanabo K., Saglain P., Channing C.P. et al. (1983):* Levels of inhibin. E. activity and steroids in human follicular fluid from normal women with PCOD. *J. Clin. Endocrinol. Metab.* 57: 24-31.
- Tassoni P., Cacciari E., Cau M., Colli C., Tosi M., Zucchini S., Cicognani A., Pirazzoli P., Salardi S., Balsamo A., Frejaville E., Cassio A. and Zappulla F. (1990):* Variability of growth hormone response to pharmacological and sleep tests performed twice in short children. *J. Clin. Endocrinol. Metab.* 71: 230-234.
- Taylor A.E. (1998):* Polycystic ovary syndrome. *Endocrinol. Metab. Clin. North. Am.* 27: 877.
- Tenenbein M. (1984):* Hyrsersitivity-like reaction to N-acetyl cystine *Vet. Hum. Toxicol.* 26: 53-85.
- Thompson L.A., Barat C.L.R., Thornton S.J., Bolton A.E. and Cooke J.D. (1993):* The effects of clomiphene citrate and cyclofenil on cervical mucus volume and receptivity over the period. *Fertil. Steril.* 59: 125.

- Tsang B.K., Armshang D.T. and Whitfield J.E. (1980):** Steroid biosynthesis by isolated human ovaries follicular cells in vitro. *J. Clin. Endocrinol. Metab.* 51: 1407.
- Van der Geer P., Hunter T. and Lindberg R.A. (1994):** Receptor protein-tyrosine kinases and their signal transduction pathways. *Ann. Rev. Cell. Biol.* 10: 251.
- Van Dessel, H.J.H.M.T., Lee, P.D.K., Faessen, G. et al. (1999):** Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.*, 84, 3030-3035.
- Vermeulen A., Stoicer R. and Verelonck C. (1971):** The apparent free testosterone concentration. An index of androgenicity. *J. Clin. Endocrinol. Metab.* 33: 759.
- Vierhapper H., Nowotny P., Czech T. et al. (1997):** How (not) to diagnose growth hormone deficiency in adults: stimulated serum concentrations of growth hormone in healthy subjects and in patient with pituitary marcoadenomas. *Metabolism.* 680-683.
- Vogt P.M., Lehuhardt M., Wagner D., Jausen V., Krieg M. and Steinau H.U. (1998):** Determination of endogeneous growth factors in human wound fluid: temporal presence and profiles of secretion. *Plast. Reconstr. Surg.* 102(1): 117.
- Volpe A., Coukos G., Dambrogio G., Artini A. and Genazzani A.R. (1991):** Follicular fluid steroid and epidermal growth factor content and in vitro estrogen release by granulosa luteal cells from patients with polycystic ovaries in an IVF/ET program. *Eur. J. Obstet. Gynecol. Report boil.* 43: 193.
- Waterfield M.D. (1991):** The role of growth factors in cancer. In : *Introduction of cellular and molecular biology of cancer.* 2nd ed., L.M. Franks and N.M. Teich (Eds.) New York. Oxford University Press. Pp. 296.
- Waterworth D.M., Bennett S.J. and Ghargni N. (1997):** Linkage and association of insulin gene VNTR regulatory polymorphism and polycystic ovary syndrome. *Lancet.* 349: 986.

- Weidmann P., deCourten M. and Bohlen L. (1993):* Insulin resistance, hyperinsulinemia and hypertension. *J. Hypertense Suppl.* Dec. 11 Suppl. 5: 527-38.
- White D.M., Leight A., Wilson C., Donaldson A. and Franks S. (1995):* Gonadotropin and gonadal steroid response to a single dose of a long-acting agonist of gonadotropin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. *Clin. Endocrinol. (Oxf.)*. 422: 478-81.
- Wiklund O., Fager G., Andersson A., et al (1996):* N-acetyl cysteine treatment lowers plasma homocysteine but not serum lipoprotein (a) levels. *Atherosclerosis*. 119: 99-106.
- Wood W.I., Cachianes G., Henzel W.J., Winslow G.a., Spencer S.A., Hellmiss R., Martin J.L. and Baxter R.C. (1988):* Cloning and expression of GH dependant IGF binding proteins. *Mol. Endocrinol.* 2: 1176-1185.
- Yen H.C., Futterweit W. and Thorton J.C. (1987):* Polycystic ovarian disease. U.S. feature n 104 patients. *Radiology*. 163: 111-116.
- Yen S.S.C. (1980):* The polycystic ovary syndrome. *Clin. Endocrinology*. 12: 177.
- Yen S.S.C. (1991):* Hronic anovulation caused by peripheral endocrine disorders. In Yen S.S.C., Jaffe Br. (eds). *Reproductive endocrinology*. Philadelphia. W.B. Saunders. 576: 630.
- Young S.L., Opsahl M.S. and Fritz M.A. (1999):* Serum concentrations of clomiphene and zuclophene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women. *Fertil. Steril.* 71(4): 639-44.
- Yu H. and Berkel (1999):* Insulin-like growth factors and cancer. *J. La. State Med. Soc.* 151(4): 218-223.
- Zapf J., Houri C., Waldvogel M. and Froesch E.R. (1986):* Acute metabolic effects and half-lives of intravenously administered insulin like growth factors I and II in normal and hypophysectomized rats. *J. Clin. Invest.* 77: 1768-1775.
- Zapf J., Kiefer M., Merryweather J., Masiarz F., Bauer D., Born W., Fischer J.A. and Froesch E.R. (1990):* Isolation from adult

human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia. J. Biol. Chem., 165: 14892-14898.

Zapf J., Schmid C. and Froesch E.R. (1984): biological and immunological properties of IGF-I and IGF-II. Cin. Endocrinol. Metab. 13: 7-12.

Zapf J., Schoenle E. and Froesch E.R. (1987): Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. Eur. J. Biochem. 87: 285.

Zhang L.H., Rodriguez H. and Ohno S. (1996): Serine phosphorylation of human P_{450c17} increase 17, 20- lyase activity, implications for adrenarche and the polycystic ovary syndrome. Proc. Natl. Acad. Sci. USA. 92: 10619.

Zimet I. (1988): Acetyl cysteine. A drug that is much more than a mucokinetic. Biomed of pharma cother 42: 513-520.

- Poretsky L. and Kalin M.F. (1987):* The gonadotropic function of insulin. *Endocr. Rev.* 8: 132.
- Powell D.R., Rosenfeld R.G., Baker B.K., Liu F. and Hintz R.L. (1986):* Serum somatomedin levels in adults with chronic renal failure. The importance of measuring insulin-like growth factor I (IGFI) and IGFII in acid chromatographed uremic serum. *J. Clin. Endocrinol. Metab.*; 63: 1186-1192.
- Preece H.A. (1997):* Making a rational diagnosis of growth hormone deficiency. *J. Pediatr.* 131 (1 part 2); S61-S64.
- Rajarm S., Baylink D.J. and Mohan S. (1997):* Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. *Endocr. Rev.*; 18: 801-031.
- Rank M.B., Schweizer R., Elmlinger M.W., Weber K., Binder G., Schwarze C.P., Woldman H.A. (2001):* Relevance of IGF-I, IGFBP-3 and IGFBP-2 measurement during GH treatment of GH-deficient and non-GH-deficient children and adolescents. *Horm. Res.*; 55(3): 115-124.
- Ranke M.B., Blum W.F. and Frisch H. (1989):* The acid-stable subunit of insulin-like growth factor binding protein (IGFBP-3) in disorders of growth. In : Drop SLS, Hintz RL (eds) *Insulin-like growth factor binding proteins*. Excerpta. Medica. Amsterdam. Pp 103-113.
- Raphael R. and Jean C.S. (1998):* Growth disorders. In *Biochemical basis of pediatric disease* ed. By Steven J., Nader R. and Jocelyn M. 3rd ed. By American Association for Clinical Chemistry. 157-179.
- Ravnikar V.A., eland-Hirsch K., Schiff I., Tulchinsky D. and Ryan K.J. (1983):* Peripheral immunoreactive LHRH concentration in polycystic ovary syndrome. Presented at the meeting of the society for gynecologic investigations. Washington. DC. March. 17-20.
- Reavens G.M. (1988):* Role of insulin resistance in human disease. *Diabetes.* 37: 1595.
- Rebar R., Judd H.L. and Yen S.S.C. (1976):* Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. *J. Clin. Invest.* 57: 1320.